Ubiquitin activating enzyme

Overview of ubiquitination (ubiquitylation)

Ubiquitin-activating enzyme (E1) starts the ubiquitination process (Figure 1). The E1 enzyme along with ATP binds to the ubiquitin protein. The E1 enzyme then passes the ubiquitin protein to a second protein, called Ubiquitin carrier or conjugation protein (E2). The E2 protein complexes with an Ubiquitin protein ligase (E3). This Ubiquitin protein ligase recognizes which protein needs to be tagged and catalyzes the transfer of ubiquitin to that protein. This pathway repeats itself until the target protein has a full chain of ubiquitin attached to itself.

Structure and mechanism

At the start of the ubiquitination cascade, the E1 enzyme (Figure 2) binds ATP-Mg²⁺ and ubiquitin and catalyses ubiquitin C-terminal acyl adenylation. In the next step a catalytic cysteine (Figure 3) on the E1 enzyme attacks the ubiquitin-AMP complex through acyl substitution, simultaneously creating a thioester bond and an AMP leaving group. Finally, the E1~ubiquitin complex transfers ubiquitin to an E2 enzyme through a transthioesterification reaction, in which an E2 catalytic cysteine attacks the backside of the E1~ubiquitin complex. However, the transthioesterification process is very complicated, as both E1 and E2 enzymes form an intermediate complex wherein both enzymes undergo a series of conformational changes in order to bind with one another.

Throughout this mechanism, the E1 enzyme is bound to two ubiquitin molecules. Although this secondary ubiquitin is similarly adenylated, it does not form the same thioester complex described previously. The function of the secondary ubiquitin remains largely unknown, however it is believed that it may facilitate conformational changes seen in the E1 enzyme during the transthioesterification process.

Isozymes

The following human genes encode ubiquitin-activating enzymes:

Disease association

The ubiquitin-proteasome system is critical to appropriate protein degradation within cells. Dysfunctions of this system can disrupt cellular homeostasis and lead to a host of disorders. In normally functioning cells, the covalent linkage of ubiquitin or ubiquitin-like protein to a target protein changes the target protein’s surface. These ubiquitinylated proteins are subject to degradation by proteolytic and non-proteolytic pathways. If this system malfunctions, numerous inherited and acquired diseases may result, such as cancer, diabetes, stroke, Alzheimer’s disease, amyotropic lateral sclerosis, multiple sclerosis, asthma, inflammatory bowel disease, autoimmune thyroiditis, inflammatory arthritis and lupus.

Missense in UBE1 and X-linked infantile spinal muscular atrophy (XL-SMA)

Among the various disorders associated with the ubiquitin-proteasome pathway is X-linked infantile spinal muscular atrophy (XL-SMA). The fatal childhood disorder is associated with loss of anterior horn cells and infantile death. Clinical features include hypotonia, areflexia, and multiple congenital contractures. In a large-scale mutation analysis, screening of six XL-SMA families provided results indicating two novel missense mutations in two families and a novel synonymous C->T substitution in another three families[footnote]. All of these detected mutations were located in exon 15 of the UBE1 gene (the gene encoding ubiquitin-activating enzyme) and were observed to segregate with disease in the families. In brevity, UBE1 missense may lead to a disturbed complex building with gigaxonin, a protein involved in axonal structure and neuronal maintenance. This can lead to impaired degradation of microtubule-associated protein 1B (MAP1B), resulting in the build-up of MAP1B protein, which may enhance neuronal cell death. Thus, mutations in UBE1 are suspected to be the cause of genetic defects in XL-SMA individuals.